Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Christopher D. Fegan"'
Autor:
Jared A. Cohen, Francesca Maria Rossi, Antonella Zucchetto, Riccardo Bomben, Lodovico Terzi-di-Bergamo, Kari G. Rabe, Massimo Degan, Agostino Steffan, Jerry Polesel, Enrico Santinelli, Idanna Innocenti, Giovanna Cutrona, Giovanni D’Arena, Gabriele Pozzato, Francesco Zaja, Annalisa Chiarenza, Davide Rossi, Francesco Di Raimondo, Luca Laurenti, Massimo Gentile, Fortunato Morabito, Antonino Neri, Manlio Ferrarini, Christopher D. Fegan, Christopher J. Pepper, Giovanni Del Poeta, Sameer A. Parikh, Neil E. Kay, Valter Gattei
Publikováno v:
Haematologica, Vol 105, Iss 6 (2020)
We present a laboratory-based prognostic calculator (designated CRO score) to risk stratify treatment-free survival in early stage (Rai 0) chronic lymphocytic leukemia (CLL) developed using a training-validation model in a series of 1,879 cases from
Externí odkaz:
https://doaj.org/article/406de82bd1c54eb29a139ecbe8f5826e
Autor:
Thomas Lewis, David B. Corcoran, David E. Thurston, Peter J. Giles, Kevin Ashelford, Elisabeth J. Walsby, Christopher D. Fegan, Andrea G.S. Pepper, Khondaker Miraz Rahman, Chris Pepper
Publikováno v:
Haematologica, Vol 106, Iss 4 (2020)
Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are incurable hematological malignancies that are pathologically linked with aberrant NF-κB activation. In this study, we identified a group of novel C8-linked benzofused Pyrrolo[2,1-c][1,
Externí odkaz:
https://doaj.org/article/0911458f4f234882b035a6312aa7bbe9
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Supplemental Figure 3. Mean (SD) TIRA plasma concentration. Cycle 1 Day 8 data are shown in patients receiving TIRA monotherapy with A) TIRA/IDELA, and B) TIRA/ENTO*
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11dcc13096ac288a3c0fe922698b5f6f
https://doi.org/10.1158/1078-0432.22476726.v1
https://doi.org/10.1158/1078-0432.22476726.v1
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Supplemental Table 1 summarizes study inclusion and exclusion criteria. Supplemental Table 2 shows the doses and dose-escalation strategy used in this study. Supplemental Table 3 defines the dose-limiting toxicities that guided dose escalation. Suppl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2661752db628906be946811e30742a6f
https://doi.org/10.1158/1078-0432.22476717
https://doi.org/10.1158/1078-0432.22476717
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Supplemental Figure 4. Free BTK levels at baseline and trough TIRA concentration for CLL patients treated with 80 mg TIRA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14a30975b8192d0017300139da2604cd
https://doi.org/10.1158/1078-0432.22476720.v1
https://doi.org/10.1158/1078-0432.22476720.v1
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Supplemental Figure 2. Patient disposition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de2f892b658eb79b3f7169372bcb174e
https://doi.org/10.1158/1078-0432.22476729
https://doi.org/10.1158/1078-0432.22476729
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Purpose:Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of escape pathways and deepen responses. This open-label, phase Ib, sequential dose-e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf6dda7779f6dd51726c8df152e2017a
https://doi.org/10.1158/1078-0432.c.6529473
https://doi.org/10.1158/1078-0432.c.6529473
Autor:
Kevin, Norris, Peter, Hillmen, Andrew, Rawstron, Robert, Hills, Duncan M, Baird, Christopher D, Fegan, Chris, Pepper
Publikováno v:
Leukemia
We have previously shown that dividing patients with CLL into those with telomeres inside the fusogenic range (TL-IFR) and outside the fusogenic range (TL-OFR) is powerful prognostic tool. Here, we used a high-throughput version of the assay (HT-STEL
Publikováno v:
Journal of Advanced Nursing. 38:407-415
The safety and effectiveness of a nurse-led anticoagulant service Aim. The aim of this study was to compare the safety and effectiveness of anticoagulant nurses and a consultant haematologist in managing anticoagulant patients in a hospital outpatien
Autor:
Christopher J, Pepper, Rachel M, Hambly, Christopher D, Fegan, Patrick, Delavault, David E, Thurston
Publikováno v:
Cancer research. 64(18)
SJG-136 (NSC 694501) is a novel DNA cross-linking agent that binds in a sequence-selective manner in the minor groove of the DNA helix. It is structurally novel compared with other clinically used DNA cross-linking agents and has exhibited a unique m